Cita APA (7a ed.)
Levy, B., Barlesi, F., Paz-Ares, L., Bennouna, J., Erman, M., Isla, D., & Felip Font, E. (2022). Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Elsevier.
Cita Chicago Style (17a ed.)
Levy, Benjamin, Fabrice Barlesi, Luis Paz-Ares, Jaafar Bennouna, Mustafa Erman, Dolores Isla, y Enriqueta Felip Font. Phase II Study of Afatinib Plus Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung Following Progression During or After First-line Chemotherapy (LUX-Lung-IO). Elsevier, 2022.
Cita MLA (9a ed.)
Levy, Benjamin, et al. Phase II Study of Afatinib Plus Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung Following Progression During or After First-line Chemotherapy (LUX-Lung-IO). Elsevier, 2022.
Precaución: Estas citas no son 100% exactas.